The purpose of this training program is to prepare postdoctoral researchers for careers in immunologic research that will enable them to have a significant impact on the prevention, diagnosis and treatment of cancer. Over the past decade, the field of immunology has witnessed an unprecedented level of discovery on every front. These exciting advances have led to an improved understanding of how cancers evade the immune system and how innate and specific immunity can be manipulated to generate an anti-tumor immune response. In order to translate this new knowledge into effective treatments for cancer, it will be necessary to train a new generation of immunologists who are well versed in the most recent concepts in immunology. Trainees will engage in an intensive program of immunologic research under the guidance of an accomplished mentor with expertise in a specific area of immunology. This will permit the young investigator to develop a focused immunologic research question and relate it to important clinical and scientific problems. In order that they have thorough exposure to the principles underlying the conduct of immunologic research, trainees will participate in a carefully designed program of courses, conferences, and meetings sponsored by the Ohio State University Comprehensive Cancer Center (OSUCCC) and the Immunology Program. Trainees will also benefit from significant exposure to related disciplines such as bioinformatics, biostatistics, human cancer genetics, translational medicine, and experimental therapeutics, as well as training in grant writing and the responsible conduct of research. Trainees will be introduce to state of the art methodologies and scientific techniques. This program will encourage the participation of both physician-scientists and trainees with a basic science background in order to enhance the exchange of ideas, stimulate intellectual curiosity, and broaden the perspectives of the participants. There has been and will continue to be a concerted effort to recruit persons from under-represented groups into this program. Successful completion of this inter-disciplinary training program will foster the development of the trainee's scientific research skills in preparation for an immunologic research career that will have a positive impact on the health needs of our nation's cancer patients. Indeed, all 25 former trainees have continued with academic pursuits and have maintained the expected career trajectory. Seventeen of these former trainees are still involved in tumor immunology research (of which 10 have garnered staff positions at academic institutions) and four others remain in medical training. Since the last renewal, three trainees from under-represented groups were recruited to this training program.

Public Health Relevance

The purpose of this training program is to prepare post-doctoral researchers for careers in immunologic research so that they can have a significant impact on the prevention, diagnosis and treatment of cancer. Successful completion of this will foster the development of the trainee's scientific research skills in preparation for an immunologic research career that will have a positive impact on the health needs of our nation's cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA090223-16A1
Application #
9793558
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
2002-07-25
Project End
2024-08-31
Budget Start
2019-09-19
Budget End
2020-08-31
Support Year
16
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Ohio State University
Department
Surgery
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Willis, William L; Wang, Linan; Wada, Takuma Tsuzuki et al. (2018) The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens. J Biol Chem 293:8394-8409
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424
Pyter, Leah M; Suarez-Kelly, Lorena P; Carson 3rd, William E et al. (2017) Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. Behav Brain Res 330:108-117
Suarez-Kelly, Lorena P; Campbell, Amanda R; Rampersaud, Isaac V et al. (2017) Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine 13:909-920
Latchana, Nicholas; Abrams, Zachary B; Howard, J Harrison et al. (2017) Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights 11:1177932217694837
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Talbert, Erin E; Yang, Jennifer; Mace, Thomas A et al. (2017) Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther 16:344-356
Yang, Jennifer; Farren, Matthew R; Ahn, Daniel et al. (2017) Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets 21:485-498

Showing the most recent 10 out of 70 publications